Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 70
Filtrar
Mais filtros

Medicinas Complementares
Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Front Immunol ; 12: 627173, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33777010

RESUMO

Mucosal-associated invariant T (MAIT) cells are a population of innate-like T cells that utilize a semi-invariant T cell receptor (TCR) α chain and are restricted by the highly conserved antigen presenting molecule MR1. MR1 presents microbial riboflavin biosynthesis derived metabolites produced by bacteria and fungi. Consistent with their ability to sense ligands derived from bacterial sources, MAIT cells have been associated with the immune response to a variety of bacterial infections, such as Mycobacterium spp., Salmonella spp. and Escherichia coli. To date, MAIT cells have been studied in humans, non-human primates and mice. However, they have only been putatively identified in cattle by PCR based methods; no phenotypic or functional analyses have been performed. Here, we identified a MAIT cell population in cattle utilizing MR1 tetramers and high-throughput TCR sequencing. Phenotypic analysis of cattle MAIT cells revealed features highly analogous to those of MAIT cells in humans and mice, including expression of an orthologous TRAV1-TRAJ33 TCR α chain, an effector memory phenotype irrespective of tissue localization, and expression of the transcription factors PLZF and EOMES. We determined the frequency of MAIT cells in peripheral blood and multiple tissues, finding that cattle MAIT cells are enriched in mucosal tissues as well as in the mesenteric lymph node. Cattle MAIT cells were responsive to stimulation by 5-OP-RU and riboflavin biosynthesis competent bacteria in vitro. Furthermore, MAIT cells in milk increased in frequency in cows with mastitis. Following challenge with virulent Mycobacterium bovis, a causative agent of bovine tuberculosis and a zoonosis, peripheral blood MAIT cells expressed higher levels of perforin. Thus, MAIT cells are implicated in the immune response to two major bacterial infections in cattle. These data suggest that MAIT cells are functionally highly conserved and that cattle are an excellent large animal model to study the role of MAIT cells in important zoonotic infections.


Assuntos
Infecções Bacterianas/imunologia , Bovinos/imunologia , Células T Invariantes Associadas à Mucosa/imunologia , Animais , Citocinas/farmacologia , Feminino , Antígenos de Histocompatibilidade Classe I/imunologia , Humanos , Masculino , Camundongos , Antígenos de Histocompatibilidade Menor/imunologia , Fenótipo , Ribitol/análogos & derivados , Ribitol/farmacologia , Uracila/análogos & derivados , Uracila/farmacologia
2.
PLoS One ; 15(12): e0240338, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33306682

RESUMO

Thyroid hormones are important modulators of metabolic activity in mammals and alter cholesterol and fatty acid levels through activation of the nuclear thyroid hormone receptor (THR). Currently, there are several THRß agonists in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) that have demonstrated the potential to reduce liver fat and restore liver function. In this study, we tested three THRß-agonism-based NASH treatment candidates, GC-1 (sobetirome), MGL-3196 (resmetirom), and VK2809, and compared their selectivity for THRß and their ability to modulate the expression of genes specific to cholesterol and fatty acid biosynthesis and metabolism in vitro using human hepatic cells and in vivo using a rat model. Treatment with GC-1 upregulated the transcription of CPT1A in the human hepatocyte-derived Huh-7 cell line with a dose-response comparable to that of the native THR ligand, triiodothyronine (T3). VK2809A (active parent of VK2809), MGL-3196, and VK2809 were approximately 30-fold, 1,000-fold, and 2,000-fold less potent than T3, respectively. Additionally, these relative potencies were confirmed by quantification of other direct gene targets of THR, namely, ANGPTL4 and DIO1. In primary human hepatocytes, potencies were conserved for every compound except for VK2809, which showed significantly increased potency that was comparable to that of its active counterpart, VK2809A. In high-fat diet fed rats, a single dose of T3 significantly reduced total cholesterol levels and concurrently increased liver Dio1 and Me1 RNA expression. MGL-3196 treatment resulted in concentration-dependent decreases in total and low-density lipoprotein cholesterol with corresponding increases in liver gene expression, but the compound was significantly less potent than T3. In conclusion, we have implemented a strategy to rank the efficacy of THRß agonists by quantifying changes in the transcription of genes that lead to metabolic alterations, an effect that is directly downstream of THR binding and activation.


Assuntos
Hepatopatia Gordurosa não Alcoólica/tratamento farmacológico , Receptores beta dos Hormônios Tireóideos/agonistas , Transcrição Gênica/efeitos dos fármacos , Acetatos/farmacologia , Acetatos/uso terapêutico , Proteína 4 Semelhante a Angiopoietina/metabolismo , Animais , Linhagem Celular Tumoral , LDL-Colesterol/sangue , LDL-Colesterol/metabolismo , Dieta Hiperlipídica/efeitos adversos , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Hepatócitos , Humanos , Iodeto Peroxidase/genética , Iodeto Peroxidase/metabolismo , Fígado/efeitos dos fármacos , Fígado/metabolismo , Fígado/patologia , Malato Desidrogenase/genética , Malato Desidrogenase/metabolismo , Masculino , Hepatopatia Gordurosa não Alcoólica/sangue , Hepatopatia Gordurosa não Alcoólica/etiologia , Hepatopatia Gordurosa não Alcoólica/patologia , Organofosfonatos/farmacologia , Organofosfonatos/uso terapêutico , Fenóis/farmacologia , Fenóis/uso terapêutico , Cultura Primária de Células , Piridazinas/farmacologia , Piridazinas/uso terapêutico , Ratos , Uracila/análogos & derivados , Uracila/farmacologia , Uracila/uso terapêutico
3.
Plant Cell Rep ; 39(8): 1013-1028, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32328702

RESUMO

KEY MESSAGE: Induction of biphasic interphase-mitotic cells and PCC is connected with an increased level of metabolism in root meristem cells of Allium cepa. Previous experiments using primary roots of Allium cepa exposed to low concentrations of hydroxyurea have shown that long-term DNA replication stress (DRS) disrupts essential links of the S-M checkpoint mechanism, leading meristem cells either to premature chromosome condensation (PCC) or to a specific form of chromatin condensation, establishing biphasic organization of cell nuclei with both interphase and mitotic domains (IM cells). The present study supplements and extends these observations by describing general conditions under which both abnormal types of M-phase cells may occur. The analysis of root apical meristem (RAM) cell proliferation after prolonged mild DRS indicates that a broad spectrum of inhibitors is capable of generating PCC and IM organization of cell nuclei. These included: 5-aminouracil (5-AU, a thymine antagonist), characterized by the highest efficiency in creating cells with the IM phenotype, aphidicolin (APH), an inhibitor of DNA polymerase α, 5-fluorodeoxyuridine (FUdR), an inhibitor of thymidylate synthetase, methotrexate (MTX), a folic acid analog that inhibits purine and pyrimidine synthesis, and cytosine arabinoside (Ara-C), which inhibits DNA replication by forming cleavage complexes with topoisomerase I. As evidenced using fluorescence-based click chemistry assays, continuous treatment of onion RAM cells with 5-AU is associated with an accelerated dynamics of the DNA replication machinery and significantly enhanced levels of transcription and translation. Furthermore, DRS conditions bring about an intensified production of hydrogen peroxide (H2O2), depletion of reduced glutathione (GSH), and some increase in DNA fragmentation, associated with only a slight increase in apoptosis-like programmed cell death events.


Assuntos
Replicação do DNA/efeitos dos fármacos , Interfase/efeitos dos fármacos , Meristema/citologia , Mitose/efeitos dos fármacos , Cebolas/citologia , Uracila/análogos & derivados , Apoptose/efeitos dos fármacos , Núcleo Celular/efeitos dos fármacos , Núcleo Celular/metabolismo , Dano ao DNA , Fragmentação do DNA/efeitos dos fármacos , Regulação da Expressão Gênica de Plantas/efeitos dos fármacos , Glutationa/metabolismo , Peróxido de Hidrogênio/metabolismo , Cebolas/genética , Biossíntese de Proteínas/efeitos dos fármacos , Espécies Reativas de Oxigênio/metabolismo , Plântula/efeitos dos fármacos , Plântula/metabolismo , Transcrição Gênica/efeitos dos fármacos , Uracila/farmacologia
4.
J Colloid Interface Sci ; 552: 166-178, 2019 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-31125827

RESUMO

HYPOTHESIS: Invoking cooperative assembly of the uracil-functionalized supramolecular polymer BU-PPG [uracil end-capped poly(propylene glycol)] upon association with the nucleobase adenine derivative A-MA [methyl 3-(6-amino-9H-purin-9-yl)propanoate] as a model drug provides a new concept to control and tune the properties of supramolecular complexes and holds significant potential for the development of safer, more effective drug delivery systems. EXPERIMENTS: BU-PPG and A-MA were successfully developed and exhibited specific recognition and high affinity, which enabled reversible complementary adenine-uracil (A-U) hydrogen bonding-induced formation of spherical micelles in aqueous solution. The self-assembly and controllable A-MA release behavior of BU-PPG/A-MA micelles were studied using morphological analysis and optical and light scattering techniques to investigate the effect of photoirradiation and temperature on the complementary hydrogen bond interactions between BU-PPG and A-MA. FINDINGS: The resulting micelles possess unusual physical properties, including controlled photoreactivity kinetics, controllable self-assembled morphology and low cytotoxicity in vitro, as well as reversible temperature-responsive behavior. Importantly, irradiated micelles exhibited excellent long-term structural stability under normal physiological conditions and serum disturbance. Increasing the temperature triggered rapid release of A-MA by disrupting A-U complexes. These findings represent an entirely new, promising strategy for the development of multi-controlled release drug delivery nanocarriers based on complementary hydrogen bonding interactions.


Assuntos
Adenina/química , Preparações de Ação Retardada/química , Raios Ultravioleta , Uracila/química , Adenina/análogos & derivados , Adenina/farmacologia , Sobrevivência Celular/efeitos dos fármacos , Preparações de Ação Retardada/farmacologia , Portadores de Fármacos/química , Portadores de Fármacos/farmacologia , Sistemas de Liberação de Medicamentos , Células HeLa , Humanos , Ligação de Hidrogênio , Interações Hidrofóbicas e Hidrofílicas , Micelas , Nanopartículas/química , Polímeros/síntese química , Polímeros/química , Polímeros/farmacologia , Temperatura , Uracila/farmacologia
5.
J Phys Chem B ; 121(25): 6139-6147, 2017 06 29.
Artigo em Inglês | MEDLINE | ID: mdl-28574710

RESUMO

The propensity of 5-selenocyanatouracil (SeCNU) to decomposition induced by attachment of electron was scrutinized with the G3B3 composite quantum-chemical method and radiolytic studies. Favorable thermodynamic (Gibbs free reaction energy of -13.65 kcal/mol) and kinetic (Gibbs free activation energy of 1.22 kcal/mol) characteristics revealed by the G3B3 free energy profile suggest SeCNU to be sensitive to electron attachment. The title compound was synthesized in the reaction between uracil and selenocyanogen chloride in acetic acid. Then, an aqueous and deoxygenated solution of the HPLC purified compound containing tert-butanol as a hydroxyl radical scavenger was irradiated with X-rays. SeCNU radio-degradation results in two major products: the U-Se-Se-U dimer and the adduct of the ●OtBu radical to the U-Se● radical, U-Se-OtBu. The effects of radiolysis as well as the results of G3B3 calculations point to U-Se● as the primary product of dissociative electron attachment to SeCNU. The MTT test shows that SeCNU is nontoxic in vitro in concentrations equal to or lower than 10-6 M. Ionizing radiation will probably induce cytotoxic intra- and interstrand DNA cross-links as well as protein-DNA cross-links in the genomic DNA labeled with SeCNU.


Assuntos
Elétrons , Radical Hidroxila/química , Selênio/química , Uracila/farmacologia , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Humanos , Radical Hidroxila/síntese química , Radical Hidroxila/farmacologia , Células MCF-7 , Estrutura Molecular , Teoria Quântica , Selênio/farmacologia , Termodinâmica , Uracila/química , Raios X
6.
Cancer J ; 22(3): 205-10, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27341600

RESUMO

Increasingly prolonged survival in metastatic colorectal cancer has paralleled the approval of new agents alone and in combination. Most recently, several new agents have sought approval in the heavily pretreated setting, after treatment with standard chemotherapies, alone and in combination, and with anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor (for patients with RAS wild-type tumors). These agents have included the multitargeted tyrosine kinase inhibitor (TKI), regorafenib, and the novel antimetabolite combination, TAS-102. Both of these showed improvement in progression-free survival and overall survival compared with placebo controls and were approved in the United States and the rest of the world. Benefits of treatment and toxicities are discussed. Nintedanib, another multitargeted TKI, is already approved by the European Medicines Evaluation Agency for non-small cell lung cancer and has been studied in a similar phase III trial. Results are pending. The risks and benefits of each agent are discussed.


Assuntos
Antineoplásicos/uso terapêutico , Neoplasias Colorretais/tratamento farmacológico , Animais , Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Ensaios Clínicos como Assunto , Neoplasias Colorretais/mortalidade , Neoplasias Colorretais/patologia , Combinação de Medicamentos , Avaliação Pré-Clínica de Medicamentos , Humanos , Terapia de Alvo Molecular , Inibidores de Proteínas Quinases/administração & dosagem , Inibidores de Proteínas Quinases/efeitos adversos , Inibidores de Proteínas Quinases/uso terapêutico , Pirrolidinas , Retratamento , Timina , Resultado do Tratamento , Trifluridina/farmacologia , Trifluridina/uso terapêutico , Uracila/análogos & derivados , Uracila/farmacologia , Uracila/uso terapêutico
7.
Stem Cells ; 34(8): 2016-25, 2016 08.
Artigo em Inglês | MEDLINE | ID: mdl-27090194

RESUMO

Glioblastoma (GBM), one of the most malignant human cancers, frequently recurs despite multimodal treatment with surgery and chemo/radiotherapies. GBM-initiating cells (GICs) are the likely cell-of-origin in recurrences, as they proliferate indefinitely, form tumors in vivo, and are resistant to chemo/radiotherapies. It is therefore crucial to find chemicals that specifically kill GICs. We established temozolomide (the standard medicine for GBM)-resistant GICs (GICRs) and used the cells for chemical screening. Here, we identified 1-(3-C-ethynyl-ß-d-ribopentofuranosyl) uracil (EUrd) as a selective drug for targeting GICRs. EUrd induced the death in GICRs more effectively than their parental GICs, while it was less toxic to normal neural stem cells. We demonstrate that the cytotoxic effect of EUrd on GICRs partly depended on the increased expression of uridine-cytidine kinase-like 1 (UCKL1) and the decreased one of 5'-nucleotidase cytosolic III (NT5C3), which regulate uridine-monophosphate synthesis positively and negatively respectively. Together, these findings suggest that EUrd can be used as a new therapeutic drug for GBM with the expression of surrogate markers UCKL1 and NT5C3. Stem Cells 2016;34:2016-2025.


Assuntos
Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/patologia , Dacarbazina/análogos & derivados , Avaliação Pré-Clínica de Medicamentos , Glioblastoma/tratamento farmacológico , Glioblastoma/patologia , Uracila/uso terapêutico , Uridina/análogos & derivados , 5'-Nucleotidase/metabolismo , Animais , Carcinogênese/metabolismo , Carcinogênese/patologia , Pontos de Checagem do Ciclo Celular/efeitos dos fármacos , Morte Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Dacarbazina/farmacologia , Dacarbazina/uso terapêutico , Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos , Glicoproteínas/metabolismo , Humanos , Camundongos SCID , Temozolomida , Uracila/farmacologia , Uridina/farmacologia , Uridina/uso terapêutico
8.
Bioorg Med Chem Lett ; 25(20): 4382-6, 2015 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-26387442

RESUMO

Colocasia esculenta (L.) Schoot (taro) is one of the most common crops in the world. Its rhizome was a tonic medicine and accustomed to treat some gastrointestinal disorders in traditional Chinese medicine. Today, the taro was further developed as anticancer prescription in herbal therapy. However, the mucilage of the fresh taro has irritation, and causes itchy feeling. The components in the mucilage were not evident up to now. Two active compounds, uracil and glycol-protein taro lectin (Accession number: A5HMM7), were purified and identified from the fresh taro. The glycol-protein taro lectin showed nerve stimulation activity on dorsal root ganglion (DRG) neurons from GCaMP transgenic mice at the concentration of 1mg/mL.


Assuntos
Colocasia/química , Lectinas/isolamento & purificação , Prurido/induzido quimicamente , Uracila/isolamento & purificação , Animais , Cromatografia Líquida , Relação Dose-Resposta a Droga , Gânglios Espinais/efeitos dos fármacos , Lectinas/química , Lectinas/farmacologia , Camundongos , Camundongos Transgênicos , Modelos Moleculares , Neurônios/efeitos dos fármacos , Relação Estrutura-Atividade , Espectrometria de Massas em Tandem , Uracila/química , Uracila/farmacologia
9.
Zhong Yao Cai ; 37(5): 752-5, 2014 May.
Artigo em Chinês | MEDLINE | ID: mdl-25335278

RESUMO

OBJECTIVE: To study the alkaloids of Cervi Cornu Pantotrichum and its effect on murine splenocytes proliferation. METHODS: The constituents isolation and purification from Cervi Cornu Pantotrichum was carried out by reported column chromatography including Sephadex LH-20 and MCI (CHP20P) and their structures were elucidated on the basis of spectral compounds. The method of MTT was used to examine the effects of eight alkaloids and total alkaloids content (TAC) of Cervi Cornu Pantotrichum on murine splenocytes proliferation. RESULTS: Eleven compounds were isolated from Cervi Cornu Pantotrichum, and their structures were identified as follows: uracil (1), hypoxanthine (2), uridine (3) inosine (4), guanosine (5), 2'-deoxyguanosine (6), guanine (7), thymidine (8), thymine (9), cytidine (10) and adenosine (11). By the experiment of murine splenocytes proliferation activity in vitro, the results showed that the total alkaloids, uracil and adenosine had significantly promoted the proliferation of mouse spleen cells. CONCLUSION: Compounds 4 - 11 are isolated from Cervi Cornu Pantotrichum for the first time. The total alkaloids is one of the material basis of immunomodulatory effects of Cervi Cornu Pantotrichum, and uracil and adenosine are the most active.


Assuntos
Alcaloides/química , Alcaloides/farmacologia , Cervos , Cornos/química , Materia Medica/farmacologia , Medicina Tradicional Chinesa , Adenosina/química , Adenosina/isolamento & purificação , Adenosina/farmacologia , Alcaloides/isolamento & purificação , Animais , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Feminino , Masculino , Materia Medica/química , Materia Medica/isolamento & purificação , Camundongos , Baço/citologia , Uracila/química , Uracila/isolamento & purificação , Uracila/farmacologia
10.
Antimicrob Agents Chemother ; 58(8): 4476-85, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24867971

RESUMO

We characterized two additional membrane transporters (Fur4p and Dal4p) of the nucleobase cation symporter 1 (NCS1) family involved in the uptake transport of pyrimidines and related molecules in the opportunistic pathogenic yeast Candida lusitaniae. Simple and multiple null mutants were constructed by gene deletion and genetic crosses. The function of each transporter was characterized by supplementation experiments, and the kinetic parameters of the uptake transport of uracil were measured using radiolabeled substrate. Fur4p specifically transports uracil and 5-fluorouracil. Dal4p is very close to Fur4p and transports allantoin (glyoxyldiureide). Deletion of the FUR4 gene confers resistance to 5-fluorouracil as well as cross-resistance to triazoles and imidazole antifungals when they are used simultaneously with 5-fluorouracil. However, the nucleobase transporters are not involved in azole uptake. Only fluorinated pyrimidines, not pyrimidines themselves, are able to promote cross-resistance to azoles by both the salvage and the de novo pathway of pyrimidine synthesis. A reinterpretation of the data previously obtained led us to show that subinhibitory doses of 5-fluorocytosine, 5-fluorouracil, and 5-fluorouridine also were able to trigger resistance to fluconazole in susceptible wild-type strains of C. lusitaniae and of different Candida species. Our results suggest that intracellular fluorinated nucleotides play a key role in azole resistance, either by preventing azoles from targeting the lanosterol 14-alpha-demethylase or its catalytic site or by acting as a molecular switch for the triggering of efflux transport.


Assuntos
Antifúngicos/farmacologia , Candida/efeitos dos fármacos , Proteínas Fúngicas/genética , Deleção de Genes , Regulação Fúngica da Expressão Gênica , Proteínas de Transporte de Nucleobases/genética , Proteínas de Transporte de Nucleotídeos/genética , Azóis/farmacologia , Transporte Biológico , Candida/genética , Candida/metabolismo , Cruzamentos Genéticos , Antagonismo de Drogas , Farmacorresistência Fúngica , Flucitosina/farmacologia , Fluoruracila/farmacologia , Proteínas Fúngicas/metabolismo , Testes de Sensibilidade Microbiana , Proteínas de Transporte de Nucleobases/metabolismo , Proteínas de Transporte de Nucleotídeos/metabolismo , Esterol 14-Desmetilase/genética , Esterol 14-Desmetilase/metabolismo , Uracila/farmacologia , Uridina/análogos & derivados , Uridina/farmacologia
11.
Hum Mol Genet ; 21(8): 1877-87, 2012 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-22246293

RESUMO

Phenylketonuria (PKU) is caused by inherited phenylalanine-hydroxylase (PAH) deficiency and, in many genotypes, it is associated with protein misfolding. The natural cofactor of PAH, tetrahydrobiopterin (BH(4)), can act as a pharmacological chaperone (PC) that rescues enzyme function. However, BH(4) shows limited efficacy in some PKU genotypes and its chemical synthesis is very costly. Taking an integrated drug discovery approach which has not been applied to this target before, we identified alternative PCs for the treatment of PKU. Shape-focused virtual screening of the National Cancer Institute's chemical library identified 84 candidate molecules with potential to bind to the active site of PAH. An in vitro evaluation of these yielded six compounds that restored the enzymatic activity of the unstable PAHV106A variant and increased its stability in cell-based assays against proteolytic degradation. During a 3-day treatment study, two compounds (benzylhydantoin and 6-amino-5-(benzylamino)-uracil) substantially improved the in vivo Phe oxidation and blood Phe concentrations of PKU mice (Pah(enu1)). Notably, benzylhydantoin was twice as effective as tetrahydrobiopterin. In conclusion, we identified two PCs with high in vivo efficacy that may be further developed into a more effective drug treatment of PKU.


Assuntos
Hidantoínas/metabolismo , Fenilalanina Hidroxilase/metabolismo , Fenilcetonúrias/tratamento farmacológico , Uracila/análogos & derivados , Animais , Sítios de Ligação , Biopterinas/análogos & derivados , Biopterinas/metabolismo , Domínio Catalítico , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Descoberta de Drogas , Avaliação Pré-Clínica de Medicamentos , Estabilidade Enzimática , Humanos , Hidantoínas/química , Hidantoínas/farmacologia , Hidantoínas/toxicidade , Camundongos , Oxirredução , Fenilalanina/metabolismo , Fenilalanina Hidroxilase/química , Fenilalanina Hidroxilase/deficiência , Fenilalanina Hidroxilase/genética , Fenilcetonúrias/metabolismo , Dobramento de Proteína , Bibliotecas de Moléculas Pequenas , Uracila/química , Uracila/metabolismo , Uracila/farmacologia , Uracila/toxicidade
12.
Antivir Chem Chemother ; 21(6): 239-43, 2011 Jul 04.
Artigo em Inglês | MEDLINE | ID: mdl-21730371

RESUMO

BACKGROUND: Epigallocatechin gallate (EGCG), the most abundant catechin in green tea, has been reported to inhibit HIV-1 replication prior to its integration into host DNA via various proposed mechanisms; however, the specific main target(s) of EGCG remain unclear. In this study, we investigated a number of these proposed detailed mechanism(s) using a cell-based model. METHODS: Multinuclear activation of galactosidase indicator assays were used for all experiments, including examination of the time of addition and the synergisms with a nucleoside reverse transcriptase inhibitor, 3'-azido-3'-deoxythymidine (AZT). RESULTS: The experiments revealed that EGCG suppressed both HIV-1(IIIB) and HIV-2(EHO) infection in HeLa-CD4-LTR-ß-gal cells, with relatively low 50% effective concentrations of 1.6 and 2.0 µM, respectively. The inhibitory profile of EGCG generated using a time-of-addition assay was identical to that of a non-nucleoside reverse transcriptase inhibitor (NNRTI), MKC-442. Furthermore, synergistic inhibition was observed in EGCG with AZT. CONCLUSIONS: Based on our findings, EGCG appears to act mainly as an allosteric reverse transcriptase inhibitor with mechanisms different from those of currently approved NNRTIs that directly interact with the NNRTI binding pocket. Thus, EGCG is a good candidate for use as an additional or supportive anti-HIV agent derived from natural plants.


Assuntos
Fármacos Anti-HIV/farmacologia , Catequina/análogos & derivados , Inibidores da Transcriptase Reversa/farmacologia , Catequina/farmacologia , Avaliação Pré-Clínica de Medicamentos , Sinergismo Farmacológico , Infecções por HIV/tratamento farmacológico , Infecções por HIV/virologia , Transcriptase Reversa do HIV/antagonistas & inibidores , HIV-1/efeitos dos fármacos , HIV-2/efeitos dos fármacos , Células HeLa , Humanos , Transcrição Reversa/efeitos dos fármacos , Uracila/análogos & derivados , Uracila/farmacologia , Zidovudina/farmacologia
13.
Nat Prod Commun ; 5(2): 253-8, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20334138

RESUMO

The new aristolactam alkaloid toussalactam {2-hydroxy-1,6-dimethoxy-5H-dibenzo[cdf]indol-4-one} and the known ones, namely aristolactam AII, aristolactam BII, piperolactam C and aristolactam FII; 1-(2-C-methyl-beta-D-ribofuranosyl)-uracil, 3,4,5-trimethoxyphenyl-beta-D-glucopyranoside, and three catechinoids were isolated from the cytotoxic Toussaintia orientalis Verdc stem and root bark extracts, and their structures established based on analysis of spectroscopic data. The aristolactams exhibited antimicrobial and antiinflammatory activity, aristolactam FII showing almost the same level of activity as the standard anti-inflammatory agent Indomethacin. The compounds also exhibited either mild or no antiproliferative and cytotoxic activities, except aristolactam FII that showed the same level of cytotoxicity as the standard drug Camptothecin. 1-(2-C-Methyl-beta-D-ribofuranosyl)-uracil, which is being reported for the first time as a natural product, was inactive in the antibacterial, antifungal, antiinflammatory, antiproliferative and cytotoxicity assays.


Assuntos
Annonaceae/química , Alcaloides Indólicos/química , Lactamas/química , Uracila/análogos & derivados , Antibacterianos/química , Antibacterianos/farmacologia , Anti-Inflamatórios/química , Anti-Inflamatórios/farmacologia , Bactérias/efeitos dos fármacos , Alcaloides Indólicos/farmacologia , Lactamas/farmacologia , Testes de Sensibilidade Microbiana , Estrutura Molecular , Uracila/química , Uracila/farmacologia
14.
Biochem J ; 425(3): 523-30, 2010 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-19929853

RESUMO

In the present study we characterize the properties of the potent MCT1 (monocarboxylate transporter 1) inhibitor AR-C155858. Inhibitor titrations of L-lactate transport by MCT1 in rat erythrocytes were used to determine the Ki value and number of AR-C155858-binding sites (Et) on MCT1 and the turnover number of the transporter (kcat). Derived values were 2.3+/-1.4 nM, 1.29+/-0.09 nmol per ml of packed cells and 12.2+/-1.1 s-1 respectively. When expressed in Xenopus laevis oocytes, MCT1 and MCT2 were potently inhibited by AR-C155858, whereas MCT4 was not. Inhibition of MCT1 was shown to be time-dependent, and the compound was also active when microinjected, suggesting that AR-C155858 probably enters the cell before binding to an intracellular site on MCT1. Measurement of the inhibitor sensitivity of several chimaeric transporters combining different domains of MCT1 and MCT4 revealed that the binding site for AR-C155858 is contained within the C-terminal half of MCT1, and involves TM (transmembrane) domains 7-10. This is consistent with previous data identifying Phe360 (in TM10) and Asp302 plus Arg306 (TM8) as key residues in substrate binding and translocation by MCT1. Measurement of the Km values of the chimaeras for L-lactate and pyruvate demonstrate that both the C- and N-terminal halves of the molecule influence transport kinetics consistent with our proposed molecular model of MCT1 and its translocation mechanism that requires Lys38 in TM1 in addition to Asp302 and Arg306 in TM8 [Wilson, Meredith, Bunnun, Sessions and Halestrap (2009) J. Biol. Chem. 284, 20011-20021].


Assuntos
Transportadores de Ácidos Monocarboxílicos/antagonistas & inibidores , Simportadores/antagonistas & inibidores , Tiofenos/farmacologia , Uracila/análogos & derivados , Animais , Sítios de Ligação , Domínio Catalítico , Galinhas , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Eritrócitos/metabolismo , Fenilalanina/química , Ligação Proteica , Estrutura Secundária de Proteína , Estrutura Terciária de Proteína , Ratos , Uracila/farmacologia , Xenopus laevis/metabolismo
15.
Arch Pharm (Weinheim) ; 342(9): 501-6, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19637180

RESUMO

1-Substiuted 6-(3-cyanobenzoyl) and [(3-cyanophenyl)fluoromethyl]-5-ethyl-uracils were synthesized and evaluated in cell-based assays against HIV-1 wild-type and its clinically relevant non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant mutants. Some of the synthesized compounds showed activity against HIV-1 wild-type in the same range as Emivirine (MKC-442). 3-{[3-(Allyloxymethyl)-5-ethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl]fluoromethyl}-benzonitrile 11b showed moderate activity against the Y181C HIV-1 mutant strain.


Assuntos
Fármacos Anti-HIV/síntese química , Sobrevivência Celular/efeitos dos fármacos , Transcriptase Reversa do HIV/antagonistas & inibidores , HIV-1/efeitos dos fármacos , Inibidores da Transcriptase Reversa/farmacologia , Uracila/análogos & derivados , Fármacos Anti-HIV/farmacologia , Linhagem Celular , Dietilaminas , Avaliação Pré-Clínica de Medicamentos , Farmacorresistência Viral/genética , Flúor , HIV-1/genética , Estrutura Molecular , Mutação , Inibidores da Transcriptase Reversa/síntese química , Uracila/farmacologia
16.
Eur J Pharmacol ; 602(2-3): 448-54, 2009 Jan 14.
Artigo em Inglês | MEDLINE | ID: mdl-19038243

RESUMO

The combination of two agents with different but complementary mechanisms of action is a logical approach for treating patients with type 2 diabetes. Thus, we evaluated chronic combination therapy with alogliptin, a highly selective dipeptidyl peptidase-4 inhibitor that enhances the action of incretins, and pioglitazone, a thiazolidinedione that improves peripheral and hepatic insulin sensitivity. Studies were designed to investigate the chronic metabolic and pancreatic effects of alogliptin (0.03%) plus pioglitazone (0.003%) combination treatment in obese ob/ob mice. After 4-5 weeks of treatment, alogliptin significantly increased plasma active glucagon-like peptide-1 levels up to 4.1-fold and decreased plasma glucagon up to 25%, whereas pioglitazone significantly increased plasma adiponectin up to 1.3-fold. Combination treatment exhibited a complementary effect, increasing plasma insulin levels by 3.2-fold (alogliptin alone, 1.6-fold; pioglitazone alone, 1.5-fold) and decreasing glycosylated hemoglobin by 2.3% (alogliptin alone, 1.0%; pioglitazone alone, 1.5%), and non-fasting and fasting plasma glucose by 37% and 62% (alogliptin alone, 17% and 24%; pioglitazone alone, 30% and 45%), respectively. Combination treatment also decreased plasma triglycerides by 67% and non-esterified fatty acids by 25% (alogliptin alone, 24% and 11%; pioglitazone alone, 54% and 8%). Moreover, combination treatment increased pancreatic insulin content by 2.2-fold (alogliptin alone, 1.3-fold; pioglitazone alone, 1.6-fold), with no significant changes in body weight. These results indicate that combination treatment with alogliptin and pioglitazone improved glycemic control, lipid profiles and increased pancreatic insulin content in ob/ob mice by preventing incretin inactivation and improving insulin resistance. These results provide a strong argument for using alogliptin in combination with pioglitazone.


Assuntos
Glicemia/metabolismo , Inibidores da Dipeptidil Peptidase IV , Insulina/metabolismo , Lipídeos/sangue , Pâncreas/efeitos dos fármacos , Piperidinas/farmacologia , Tiazolidinedionas/farmacologia , Uracila/análogos & derivados , Animais , Peso Corporal/efeitos dos fármacos , Combinação de Medicamentos , Ingestão de Alimentos/efeitos dos fármacos , Inibidores Enzimáticos/farmacologia , Inibidores Enzimáticos/uso terapêutico , Hormônios/sangue , Hiperinsulinismo/sangue , Hiperinsulinismo/tratamento farmacológico , Masculino , Camundongos , Camundongos Obesos , Pâncreas/metabolismo , Pioglitazona , Piperidinas/uso terapêutico , Tiazolidinedionas/uso terapêutico , Uracila/farmacologia , Uracila/uso terapêutico
17.
Cell Mol Immunol ; 4(4): 295-9, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17764620

RESUMO

We evaluated the antitumor effect of combined therapy with tegafur/uracil (UFT) plus leucovorin (LV) (UFT/LV) and protein-bound polysaccharide, PSK, in three mouse models of transplantable tumors. UFT/LV showed antitumor effect against Meth A sarcoma, and the antitumor effect was enhanced when PSK given concomitantly. UFT/LV showed antitumor effect to Lewis lung carcinoma and PSK alone also showed antitumor effect at high dose, but a combination of UFT/LV and PSK resulted in no enhanced antitumor effect. Colon 26 carcinoma was weakly responsive to UFT/LV, and no enhancement of antitumor effect was found even PSK was used in combination. In conclusion, while the effect of PSK varies depending on tumor, combined use of UFT/LV and PSK may be expected to augment the antitumor effect.


Assuntos
Antineoplásicos/farmacologia , Modelos Animais de Doenças , Leucovorina/farmacologia , Proteoglicanas/farmacologia , Tegafur/farmacologia , Uracila/farmacologia , Animais , Carcinoma Pulmonar de Lewis/tratamento farmacológico , Neoplasias do Colo/tratamento farmacológico , Quimioterapia Combinada , Feminino , Leucovorina/uso terapêutico , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Proteoglicanas/uso terapêutico , Sarcoma/tratamento farmacológico , Tegafur/uso terapêutico , Uracila/uso terapêutico , Ensaios Antitumorais Modelo de Xenoenxerto
18.
Ukr Biokhim Zh (1999) ; 79(5): 145-52, 2007.
Artigo em Ucraniano | MEDLINE | ID: mdl-18357788

RESUMO

Isolation of lectins from extracts of the Sambucus nigra inflorescences and of pollen material have been performed using isoelectric focusing without carrier ampholytes (autofocusing). Fractions active in agglutination tests with different carbohydrate specificity were subjected to SDS-PAGE. The major lectin found in whole inflores-cences was GalNAc specific and is proposed to be a heterotetramer with subunits of about 30 and 33 kDa. It was called SNAflu-I. At least two other lectins were present in the pollen material and supposed to consist of identical subunits. Major positively charged lectin was Glc/Man specific with subunit of 26 kDa and called SNApol-I. Other pollen component (SNApol-II) was Gal specific with subunit of about 20 kDa. In order to elucidate cell targets sensitive for the S. nigra lectin's activity the combined effects of the lectins and transcriptional of phenazine origin on B. subtilis cells growth have been studied. Only SNApol-I demonstrated the antagonistic activity against these inhibitors in vivo. This lectin but not the SNAflu-I can also inhibit transcription in vitro. It is supposed that lectins from the same source may act in different directions on cell metabolism. Particularly one of the common targets may be the DNA-dependent synthesis of RNA.


Assuntos
Bacillus subtilis/efeitos dos fármacos , Lectinas de Plantas/isolamento & purificação , Lectinas de Plantas/farmacologia , Proteínas Inativadoras de Ribossomos/isolamento & purificação , Proteínas Inativadoras de Ribossomos/farmacologia , Sambucus nigra/química , Animais , Bacillus subtilis/genética , Sinergismo Farmacológico , Eletroforese em Gel de Poliacrilamida , Eritrócitos/citologia , Eritrócitos/efeitos dos fármacos , Flores/química , Testes de Inibição da Hemaglutinação , Humanos , Fenazinas/química , Fenazinas/farmacologia , Pólen/química , Ovinos , Uracila/análogos & derivados , Uracila/química , Uracila/farmacologia
19.
J Med Chem ; 49(8): 2579-92, 2006 Apr 20.
Artigo em Inglês | MEDLINE | ID: mdl-16610801

RESUMO

N3-substitution of the uracil ring of willardiine with a variety of carboxyalkyl or carboxybenzyl substituents produces AMPA and kainate receptor antagonists. In an attempt to improve the potency and selectivity of these AMPA and kainate receptor antagonists a series of analogues with different terminal acidic groups and interacidic group spacers was synthesized and pharmacologically characterized. (S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxythiophene-3-ylmethyl)pyrimidine-2,4-dione (43, UBP304) demonstrated high potency and selectivity toward native GLU(K5)-containing kainate receptors (K(D) 0.105 +/- 0.007 microM vs kainate on native GLU(K5); K(D) 71.4 +/- 8.3 microM vs (S)-5-fluorowillardiine on native AMPA receptors). On recombinant human GLU(K5), GLU(K5)/GLU(K6), and GLU(K5)/GLU(K2), K(B) values of 0.12 +/- 0.03, 0.12 +/- 0.01, and 0.18 +/- 0.02 microM, respectively, were obtained for 43. However, 43 displayed no activity on homomeric GLU(K6) or GLU(K7) kainate receptors or homomeric GLU(A1-4) AMPA receptors (IC(50) values > 100 microM). Thus, 43 is a potent and selective GLU(K5) receptor antagonist.


Assuntos
Alanina/análogos & derivados , Pirimidinonas/farmacologia , Receptores de Ácido Caínico/antagonistas & inibidores , Uracila/farmacologia , Ácido alfa-Amino-3-hidroxi-5-metil-4-isoxazol Propiônico/antagonistas & inibidores , Alanina/síntese química , Alanina/química , Alanina/farmacologia , Animais , Sítios de Ligação , Linhagem Celular , Avaliação Pré-Clínica de Medicamentos , Humanos , Técnicas In Vitro , Estrutura Molecular , Pirimidinonas/síntese química , Pirimidinonas/química , Ratos , Proteínas Recombinantes/antagonistas & inibidores , Relação Estrutura-Atividade , Fatores de Tempo , Uracila/análogos & derivados , Uracila/síntese química , Uracila/química
20.
Biocell ; 29(2): 169-76, 2005 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16187495

RESUMO

This work evaluated the qualitative and quantitative cellular changes induced by treatment with 5-aminouracil (5-AU) and a combination of 5-AU and caffeine in plant cells in relation to DNA damage, repaired damage, and residual damage. As biological material, Allium cepa L. root tips were used, grown in filtered water, in darkness, with aeration at constant temperature of 25 degrees C +/- 0.5. Cell populations were synchronized using 5 mM caffeine in order to study the effects of 5-AU and caffeine/5-AU combined treatment on the DNA content and their incidence in the entrance to mitosis. The results showed a delay in the G2 period due to induced DNA damage by the 5-AU and caffeine/5-AU combined treatment, shown by aberrant metaphases, anaphases and telophases. The effect of caffeine in the combined treatment was heightened in spite of lengthening the checkpoints route that retains the cells in G2. The existence of G2 checkpoints was shown in the cell population studied, inducing lesions in the DNA, chromosomic aberrations and cellular instability.


Assuntos
Cafeína/farmacologia , DNA/metabolismo , Uracila/análogos & derivados , Núcleo Celular/metabolismo , Aberrações Cromossômicas , DNA/efeitos dos fármacos , Dano ao DNA , Relação Dose-Resposta a Droga , Fase G2 , Alho/efeitos dos fármacos , Metáfase , Mitose , Inibidores de Fosfodiesterase/farmacologia , Plantas/metabolismo , Temperatura , Fatores de Tempo , Uracila/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA